Fort Lauderdale, FL, June 15, 2015 - OmniComm Systems, Inc. (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, announces the selection of Promasys® EDC by Integrated Development Associates (IDA), a Tokyo-based Pan Asian drug development company to run clinical trials in Japan and the Philippines. Japan represents the second largest pharmaceutical market in the world whereas the Philippines is one of the fastest growing markets.
“As IDA grows, we see not only the need to integrate Japan into large global studies but also the need to efficiently deliver turn-key Phase I ethnic bridging studies and stand-alone local Japan and Pan Asian clinical trials for clients,” says John Winebarger, president and CEO, IDA. “The Promasys system is an important tool that will now allow us to offer our clients with data management and EDC services in a highly reliable and cost efficient manner.”
After a thorough evaluation process of various commercially available technologies, IDA selected Promasys technology to manage its clinical data management activities. Overall Promasys was deemed to be best suited in terms of ease of use, fast study build, data quality and integrity and subject recruitment.
“OmniComm already has a strong presence in East Asia with an increasing number of customers in China, Korea and Japan” says Wolf Ondracek, senior vice president of Asian and Academic Markets at OmniComm. “Now that IDA have selected Promasys as the solution for their local and international data capture and data management needs, we will not only further strengthen our presence in the strategic Japanese market, but also enter the Philippines which is a new but important territory. We are proud that our software will be used at the Phase I facilities within the prestigious De La Salle Health Sciences Institute in Dasmariñas, as well as with IDA Japanese and their Pan Asian Phase I-IV clinical trials.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.